PLoS ONE · 2016 · 18 citations · 51 references
MedicinePharmacokineticsPharmacologyBiochemical PharmacologyDrug MetabolismPharmacogeneticsCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug-metabolizing EnzymesPhase Ii MetabolismCyp2d6 Drug MetabolismCyp2d6 GenotypeCytochrome P450 2D6Cytochrome P450 Drug MetabolismCytochrome P450 KineticsMdma ToxicityPhase Ii MetabolitesPlasma Pharmacokinetics
3,4-methylenedioxymethamphetamine (MDMA; ecstasy) metabolism is known to be stereoselective, with preference for S-stereoisomers. Its major metabolic step involves CYP2D6-catalyzed demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by methylation and conjugation. Alterations in CYP2D6 genotype and/or phenotype have been associated with higher toxicity. Therefore, the impact of CYP2D6 function on the plasma pharmacokinetics of MDMA and its phase I and II metabolites was tested by comparing extensive metabolizers (EMs), intermediate metabolizers (IMs), and EMs that were pretreated with bupropion as a metabolic inhibitor in a controlled MDMA administration study. Blood plasma samples were collected from 16 healthy participants (13 EMs and three IMs) up to 24 h after MDMA administration in a double-blind, placebo-controlled, four-period, cross-over design, with subjects receiving 1 week placebo or bupropion pretreatment followed by a single placebo or MDMA (125 mg) dose. Bupropion pretreatment increased the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from 0 to 24 h (AUC24) of R-MDMA (9% and 25%, respectively) and S-MDMA (16% and 38%, respectively). Bupropion reduced the Cmax and AUC24 of the CYP2D6-dependently formed metabolite stereoisomers of DHMA 3-sulfate, DHMA 4-sulfate, and 4-hydroxy-3-methoxymethamphetamine (HMMA sulfate and HMMA glucuronide) by approximately 40%. The changes that were observed in IMs were generally comparable to bupropion-pretreated EMs. Although changes in stereoselectivity based on CYP2D6 activity were observed, these likely have low clinical relevance. Bupropion and hydroxybupropion stereoisomer pharmacokinetics were unaltered by MDMA co-administration. The present data might aid further interpretations of toxicity based on CYP2D6-dependent MDMA metabolism.
51
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
Shufeng Zhou · Clinical Pharmacokinetics · 2009 · 759 citations
Medicine, Genetics, Pharmacology +14
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.
H. Kalant · PubMed · 2001 · 620 citations · Full text
Medicine, Pharmacology, Toxicology +17
J. Kevin Hicks, Jesse J. Swen, Caroline F. Thorn et al. · Clinical Pharmacology & Therapeutics · 2013 · 453 citations · Full text
Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humans
Rafael de la Torre, Magı́ Farré, Jordi Ortuño et al. · British Journal of Clinical Pharmacology · 2000 · 407 citations · Full text
MDMA enhances emotional empathy and prosocial behavior
Cédric M. Hysek, Yasmin Schmid, Linda D. Simmler et al. · Social Cognitive and Affective Neuroscience · 2013 · 356 citations · Full text